...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Evaluation of Injectable Chitosan-based Co-cross-linking Hydrogel for Local Delivery of Re-188-LIPO-DOX to Breast-tumor-bearing Mouse Model
【24h】

Evaluation of Injectable Chitosan-based Co-cross-linking Hydrogel for Local Delivery of Re-188-LIPO-DOX to Breast-tumor-bearing Mouse Model

机译:基于壳聚糖的乳腺携带的小鼠模型局部递送注射壳聚糖的共传送水凝胶的评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background/Aim: An injectable chitosan-based cross-linking thermosensitive hydrogel combining Re-188- and doxorubicin-encapsulated liposomes (C/GP/GE/ Re-188-LIPO-DOX) was developed for the prevention of locoregional recurrence after mastectomy. Materials and Methods: The hydrogel properties, in vitro drug release characteristics, and in vivo scintigraphy imaging attributes were investigated. Results: The gelation time of the hydrogels can be controlled to be within 5 min. Results from Fourier-transform infrared spectroscopy, scanning electron microscopy, and dynamic mechanical analysis showed that a covalent cross-linking reaction between chitosan and genipin occurred and that the hydrogel's mechanical strength and chemical stability were improved. In vitro drug release studies showed that the hydrogel can prolong the release of doxorubicin by several weeks (51.5%+/- 5.3% at 21 days). In addition, in vivo scintigraphy results suggested high retention rates (43.1%11.0% at 48 h) of the radiopharmaceutical compound at the tumor injection site. Conclusion: The preliminary results indicated that the C/GP/GE/ Re-188-LIPO-DOX radiopharmaceutical hydrogel is a potential candidate for further in vivo therapeutic evaluation.
机译:背景/目的:组合RE-188-和多柔比蛋白包封脂质体的可注射的壳聚糖的交联热敏水凝胶(C / GP / GE / RE-LIPO-DOX),用于预防乳房切除术后的局部复发。研究了材料和方法:研究了水凝胶特性,体外药物释放特性和体内闪烁的成像属性。结果:水凝胶的凝胶化时间可以控制在5分钟内。傅立叶变换红外光谱,扫描电子显微镜和动态力学分析结果表明,壳聚糖和Genipin之间的共价交联反应发生,水凝胶的机械强度和化学稳定性得到改善。体外药物释放研究表明,水凝胶可以在几周内延长多柔比星的释放(在21天的51.5%+ / - 5.3%)。此外,在肿瘤注射部位下,体内闪烁的结果表明高保留率(48小时48小时4.0%)的放射性药物化合物。结论:初步结果表明,C / GP / GE / RE-188-Lipo-Dox放射性药物水凝胶是进一步体内治疗评价的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号